High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection

Launched by SWISSE WELLNESS PTY LTD · Feb 1, 2017

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Females aged 18-65 years, inclusive
• • 2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation by a health professional
• • 3. Willing to answer questionnaires and comply with the study requirements
• • 4. Ability to swallow capsules
• • 5. Provided Written Informed Consent
• • 6. BMI \>17.5kg m2 and \<35kg m2
• Exclusion Criteria:
• • 1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1
• • 2. A history of \>5 UTIs in the last 6 months (confirmed by self-report or health professional)
• • 3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1
• • 4. Use of any antibacterial products, that in the opinion of the Medical Investigator may interfere with the study outcomes, within 28 days of Day 1
• • 5. Regular use of Vaccinium containing products (e.g. all forms of blueberries, cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or supplements) within 28 days of Day 1 at the discretion of the Medical Investigator
• • 6. Presence of an intermittent or indwelling urinary catheter
• • 7. Anatomical abnormalities of the urinary tract
• • 8. History of or known clinically significant renal or urological disease(self-reported)
• • 9. Positive urine dipstick pregnancy test at screening onDay 1, currently pregnant and/or breastfeeding
• • 10. Women of Childbearing potential not willing to use adequate and effective methods of contraception throughout the study
• • 11. Women of child bearing potential that have not been using effective methods of contraception for 14 days prior to Day 1
• • 12. History of or known clinically significant cardiac disease
• • 13. History of or known clinically significant liver disease
• • 14. History of or known clinically significant gastrointestinal disease
• • 15. History of or known metabolic disorder or diabetes
• • 16. History or presence of alcohol or illicit drug abuse,any surgical history, clinical condition or organ dysfunction that in the opinion of the Medical Investigator may affect the participant's ability to participate in the study or the study results
• • 17. Currently hospitalised or any planned hospitalisations within 1 month following the last dose of study product
• • 18. Immunocompromised participants or participants receiving immunosuppressive medication
• • 19. History of an adverse reaction or known hypersensitivity or suspected allergy to the investigational product ingredients
• • 20. Currently taking warfarin or has received Warfarin within 28 days of Day 1
• • 21. Received an investigational drug within 28 days of Day 1